Brokerages Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Target Price at $11.50

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have received an average rating of “Hold” from the four research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $11.00.

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Wednesday, January 21st. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. HC Wainwright decreased their price objective on shares of BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Rodman & Renshaw assumed coverage on shares of BioXcel Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock.

Institutional Trading of BioXcel Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Diversify Wealth Management LLC bought a new stake in shares of BioXcel Therapeutics during the 2nd quarter worth $27,000. HRT Financial LP bought a new stake in shares of BioXcel Therapeutics during the 4th quarter worth $28,000. XTX Topco Ltd purchased a new position in BioXcel Therapeutics in the second quarter worth $42,000. Goldman Sachs Group Inc. bought a new position in BioXcel Therapeutics in the first quarter valued at $50,000. Finally, Geode Capital Management LLC increased its stake in BioXcel Therapeutics by 27.7% in the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after acquiring an additional 6,120 shares during the last quarter. Hedge funds and other institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Price Performance

BTAI opened at $1.18 on Tuesday. The company has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.93. The firm has a market capitalization of $31.95 million, a P/E ratio of -0.18 and a beta of 0.30. BioXcel Therapeutics has a one year low of $1.08 and a one year high of $8.08.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.58). The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.15 million. On average, analysts expect that BioXcel Therapeutics will post -24.39 earnings per share for the current year.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.